Nexsen Ltd
NXN
Company Profile
Business description
Nexsen Ltd is a nanobiotechnology company for the development of biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for veterinary, agricultural and biosecurity applications. Its products include: GBS Rapid Sensor, Chronic Kidney Disease (CKD), Bovine Mastitis, Acute Kidney Injury (AKI), and Biosecurity Pathogen Tests (x2).
Contact
4 Bridge Street
Suite 1005
SydneyNSW2000
AUST: +61 291745388
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
We maintain our fair value estimate despite unfavourable economic conditions.
stocks
Why it’s not all bad news for Flight Centre following downgrade
Despite an earnings downgrade, shares in FLT remain undervalued.
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Our data shows buying into the IPO hype can be costly.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.20 | 1.20 | -0.01% |
| CAC 40 | 8,386.54 | 45.07 | -0.53% |
| DAX 40 | 24,681.72 | 313.11 | -1.25% |
| Dow JONES (US) | 52,058.93 | 138.31 | 0.27% |
| FTSE 100 | 10,515.20 | 14.69 | -0.14% |
| HKSE | 22,671.86 | 405.05 | -1.76% |
| NASDAQ | 25,406.79 | 48.18 | 0.19% |
| Nikkei 225 | 69,360.88 | 3,005.46 | -4.15% |
| NZX 50 Index | 13,495.24 | 2.19 | 0.02% |
| S&P 500 | 7,375.26 | 17.77 | 0.24% |
| S&P/ASX 200 | 8,764.20 | 0.20 | 0.00% |
| SSE Composite Index | 4,027.26 | 93.02 | -2.26% |